Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 12 | 2026 | 532 | 2.810 |
Why?
|
| Opiate Substitution Treatment | 5 | 2026 | 226 | 1.290 |
Why?
|
| Smoking Cessation | 3 | 2026 | 553 | 0.930 |
Why?
|
| Chronic Pain | 2 | 2025 | 157 | 0.920 |
Why?
|
| Analgesics, Opioid | 3 | 2025 | 532 | 0.890 |
Why?
|
| Acute Pain | 1 | 2025 | 20 | 0.880 |
Why?
|
| Nicotine | 1 | 2025 | 118 | 0.810 |
Why?
|
| Drug Overdose | 3 | 2025 | 123 | 0.800 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2025 | 78 | 0.790 |
Why?
|
| Veterans | 8 | 2026 | 770 | 0.720 |
Why?
|
| Mental Disorders | 2 | 2026 | 827 | 0.700 |
Why?
|
| Delay Discounting | 1 | 2020 | 3 | 0.660 |
Why?
|
| Intimate Partner Violence | 2 | 2017 | 26 | 0.630 |
Why?
|
| Anxiety | 3 | 2017 | 427 | 0.550 |
Why?
|
| Motivation | 1 | 2020 | 298 | 0.550 |
Why?
|
| Sex Offenses | 2 | 2017 | 44 | 0.530 |
Why?
|
| Crime Victims | 2 | 2017 | 39 | 0.530 |
Why?
|
| Self-Control | 1 | 2017 | 10 | 0.530 |
Why?
|
| Stalking | 1 | 2017 | 4 | 0.520 |
Why?
|
| Adaptation, Psychological | 2 | 2017 | 278 | 0.470 |
Why?
|
| Behavior Therapy | 3 | 2026 | 169 | 0.470 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 201 | 0.460 |
Why?
|
| Emotions | 1 | 2017 | 236 | 0.440 |
Why?
|
| Harm Reduction | 2 | 2025 | 34 | 0.430 |
Why?
|
| Buprenorphine | 3 | 2026 | 199 | 0.360 |
Why?
|
| Humans | 31 | 2026 | 65821 | 0.330 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2020 | 406 | 0.330 |
Why?
|
| Antidepressive Agents | 5 | 2011 | 244 | 0.310 |
Why?
|
| Alcoholism | 2 | 2025 | 329 | 0.310 |
Why?
|
| Narcotic Antagonists | 3 | 2026 | 133 | 0.290 |
Why?
|
| Patient Discharge | 2 | 2022 | 522 | 0.270 |
Why?
|
| Naltrexone | 2 | 2026 | 91 | 0.270 |
Why?
|
| Substance-Related Disorders | 2 | 2025 | 757 | 0.260 |
Why?
|
| Comorbidity | 3 | 2026 | 1122 | 0.250 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2026 | 91 | 0.240 |
Why?
|
| Tobacco Use Cessation | 1 | 2026 | 32 | 0.230 |
Why?
|
| Acceptance and Commitment Therapy | 1 | 2026 | 16 | 0.230 |
Why?
|
| Medication Adherence | 1 | 2026 | 202 | 0.220 |
Why?
|
| Students | 2 | 2017 | 227 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2011 | 809 | 0.210 |
Why?
|
| Pharmacists | 1 | 2025 | 131 | 0.200 |
Why?
|
| Tobacco Use Disorder | 1 | 2026 | 248 | 0.200 |
Why?
|
| Pain Management | 1 | 2025 | 174 | 0.190 |
Why?
|
| Suicide | 1 | 2025 | 147 | 0.190 |
Why?
|
| Adult | 12 | 2026 | 17566 | 0.170 |
Why?
|
| Aftercare | 1 | 2022 | 77 | 0.170 |
Why?
|
| Acupuncture Therapy | 2 | 2012 | 18 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 741 | 0.160 |
Why?
|
| Residential Treatment | 1 | 2020 | 34 | 0.160 |
Why?
|
| Treatment Outcome | 8 | 2022 | 5830 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 770 | 0.160 |
Why?
|
| Quality of Life | 2 | 2025 | 1267 | 0.150 |
Why?
|
| Self Efficacy | 1 | 2020 | 206 | 0.150 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2020 | 126 | 0.150 |
Why?
|
| Violence | 2 | 2017 | 171 | 0.140 |
Why?
|
| Middle Aged | 9 | 2026 | 18490 | 0.140 |
Why?
|
| Health Policy | 1 | 2020 | 191 | 0.140 |
Why?
|
| Rumination, Cognitive | 1 | 2017 | 1 | 0.140 |
Why?
|
| Behavioral Sciences | 1 | 2017 | 2 | 0.130 |
Why?
|
| Avoidance Learning | 1 | 2017 | 27 | 0.130 |
Why?
|
| Sex Factors | 3 | 2025 | 995 | 0.130 |
Why?
|
| Psychological Trauma | 1 | 2017 | 23 | 0.130 |
Why?
|
| Male | 15 | 2026 | 31397 | 0.130 |
Why?
|
| Rape | 1 | 2016 | 14 | 0.120 |
Why?
|
| Social Perception | 1 | 2016 | 44 | 0.120 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2013 | 382 | 0.120 |
Why?
|
| Female | 15 | 2026 | 34411 | 0.120 |
Why?
|
| Sexual and Gender Minorities | 1 | 2016 | 76 | 0.110 |
Why?
|
| Age Factors | 3 | 2025 | 1594 | 0.100 |
Why?
|
| Fluoxetine | 2 | 2011 | 45 | 0.100 |
Why?
|
| Hypericum | 1 | 2011 | 3 | 0.090 |
Why?
|
| Suicidal Ideation | 1 | 2013 | 133 | 0.090 |
Why?
|
| Plant Preparations | 1 | 2011 | 13 | 0.090 |
Why?
|
| Phytotherapy | 1 | 2011 | 34 | 0.080 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2025 | 549 | 0.080 |
Why?
|
| United States | 4 | 2025 | 8189 | 0.080 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2011 | 129 | 0.080 |
Why?
|
| Clonazepam | 1 | 2010 | 3 | 0.080 |
Why?
|
| Internet | 2 | 2026 | 472 | 0.080 |
Why?
|
| Nervous System Diseases | 1 | 2011 | 109 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2026 | 2649 | 0.070 |
Why?
|
| Young Adult | 5 | 2025 | 4878 | 0.070 |
Why?
|
| Double-Blind Method | 4 | 2012 | 747 | 0.070 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2008 | 13 | 0.070 |
Why?
|
| Sound | 1 | 2008 | 9 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 2013 | 475 | 0.070 |
Why?
|
| Alcohol Drinking | 2 | 2021 | 325 | 0.070 |
Why?
|
| Speech Perception | 1 | 2008 | 80 | 0.060 |
Why?
|
| Prevalence | 2 | 2024 | 1453 | 0.060 |
Why?
|
| Animals | 1 | 2025 | 21489 | 0.060 |
Why?
|
| Injections | 1 | 2026 | 84 | 0.060 |
Why?
|
| Depression | 1 | 2013 | 910 | 0.060 |
Why?
|
| Aging | 1 | 2011 | 784 | 0.060 |
Why?
|
| Professional Role | 1 | 2025 | 45 | 0.050 |
Why?
|
| Life Expectancy | 1 | 2025 | 33 | 0.050 |
Why?
|
| Adolescent | 3 | 2025 | 6365 | 0.050 |
Why?
|
| Cause of Death | 1 | 2025 | 221 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 736 | 0.050 |
Why?
|
| Aged | 4 | 2025 | 15140 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 876 | 0.050 |
Why?
|
| Time Factors | 4 | 2012 | 3777 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2024 | 216 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2026 | 6952 | 0.040 |
Why?
|
| Demography | 2 | 2013 | 178 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2026 | 763 | 0.040 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2021 | 26 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2021 | 72 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2021 | 120 | 0.040 |
Why?
|
| Narcotics | 1 | 2020 | 57 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2011 | 498 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2025 | 633 | 0.040 |
Why?
|
| Arousal | 1 | 2020 | 42 | 0.040 |
Why?
|
| Recurrence | 1 | 2022 | 665 | 0.040 |
Why?
|
| Afghan Campaign 2001- | 1 | 2020 | 67 | 0.040 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2020 | 62 | 0.040 |
Why?
|
| Risk Factors | 2 | 2025 | 5471 | 0.040 |
Why?
|
| Methadone | 1 | 2020 | 140 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2012 | 1028 | 0.030 |
Why?
|
| Ethanol | 1 | 2021 | 333 | 0.030 |
Why?
|
| Accidents, Traffic | 1 | 2017 | 140 | 0.030 |
Why?
|
| Culture | 1 | 2016 | 82 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 692 | 0.030 |
Why?
|
| Focus Groups | 1 | 2016 | 329 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 3338 | 0.030 |
Why?
|
| Psychology, Comparative | 1 | 2013 | 1 | 0.020 |
Why?
|
| Self-Assessment | 1 | 2013 | 60 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1568 | 0.020 |
Why?
|
| Executive Function | 1 | 2013 | 71 | 0.020 |
Why?
|
| Acupuncture Points | 1 | 2012 | 5 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2013 | 214 | 0.020 |
Why?
|
| Sertraline | 1 | 2011 | 58 | 0.020 |
Why?
|
| Remission Induction | 1 | 2011 | 149 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 73 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 806 | 0.020 |
Why?
|
| Outpatients | 1 | 2011 | 143 | 0.020 |
Why?
|
| Motor Activity | 1 | 2013 | 347 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 208 | 0.020 |
Why?
|
| Anti-Anxiety Agents | 1 | 2010 | 31 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 375 | 0.020 |
Why?
|
| Verbal Learning | 1 | 2008 | 21 | 0.020 |
Why?
|
| Acoustic Stimulation | 1 | 2008 | 62 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 463 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2008 | 156 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 1274 | 0.020 |
Why?
|
| Research Design | 1 | 2011 | 589 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2008 | 247 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 2113 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 2496 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 2737 | 0.010 |
Why?
|